Synergy Pharmaceuticals to Present at Aegis Capital 2013 Healthcare Conference

  Synergy Pharmaceuticals to Present at Aegis Capital 2013 Healthcare
  Conference

Aegis Capital Healthcare Conference 2013

Business Wire

NEW YORK -- September 24, 2013

Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat
gastrointestinal diseases and disorders, today announced that its President
and CEO, Gary S. Jacob, Ph.D., will present at the Aegis Capital 2013
Healthcare Conference being held at The Encore at Wynn Las Vegas, September
25-28. The presentation is scheduled for Saturday, September 28^th at 10:30
a.m. (PDT).

About Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals is a biopharmaceutical company focused on the
development of new drugs to treat patients with gastrointestinal (GI) diseases
and disorders. Synergy's lead proprietary drug candidate, plecanatide, is a
synthetic analog of the human GI hormone, uroguanylin, and functions by
activating the guanylate cyclase-C (GC-C) receptor on epithelial cells of the
GI tract. In early 2013, Synergy announced positive results from a large
multicenter trial of plecanatide in patients with chronic idiopathic
constipation (CIC) and recently completed an end-of-phase 2 meeting with the
U.S. Food and Drug Administration (FDA) covering the registration program for
plecanatide to treat CIC. Synergy is also developing plecanatide for the
treatment of irritable bowel syndrome with constipation (IBS-C), recently
announcing that it had reached the halfway mark for total enrollment in a
plecanatide phase 2b clinical trial in patients with IBS-C. Synergy’s second
GC-C agonist, SP-333, is in clinical development to treat inflammatory bowel
disease and other GI conditions and has recently completed its first phase I
trial in healthy volunteers. More information is available at
www.synergypharma.com .

Contact:

Synergy Pharmaceuticals
Media Contact
Gem Gokmen
Office: 212-584-7610
Mobile: 646-637-3208
ggokmen@synergypharma.com
or
Investor Contact
Bernard Denoyer
Office: 212-297-0020
Mobile: 203-300-8147
bdenoyer@synergypharma.com